Skip to content
In English |
En español
National Cancer Institute
at the National Institutes of Health
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
Email This Document
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
LiveHelp online chat
Popular Resources
Help Using the NCI Clinical Trials Search Form
Learn About Clinical Trials
About NCI's List of Cancer Clinical Trials
NCI Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-7 of 7 for your search:
Drug:
tigatuzumab
Find trials that include:
Any drugs shown
Trial Status:
Closed
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Open-label Study of CS1008 for Subjects With Untreated and Unresectable Pancreatic Cancer
Phase:
Phase II
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CS1008-A-U201
, NCT00521404
2.
Combination Chemotherapy With CS-1008 to Treat Ovarian Cancer
Phase:
Phase II
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CS1008-A-U205
, NCT00945191
3.
CS-1008 With Carboplatin/Paclitaxel in Chemotherapy naïve Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer (NSCLC)
Phase:
Phase II
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CS1008-A-E202
, NCT00991796
4.
CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer
Phase:
Phase II
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CS1008-A-U204
, NCT01033240
5.
Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer
Phase:
Phase II
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Closed
Age:
18 and over (19 in Alabama)
Sponsor:
Other
Protocol IDs:
F101004001 (UAB1028)
, TBCRC 019, NCT01307891
6.
Study of CS-1008 in Patients With Advanced Solid Malignancies and Lymphomas (Without Leukemic Component)
Phase:
Phase I
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CS1008-A-U101
, NCT00320827
7.
Study of CS-1008 in Combination With FOLFIRI in Patients Who Have Failed Other Treatments
Phase:
Phase I
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CS1008-A-U105
, NCT01124630
Select All on Page
Help with Results
We Can Answer Your Questions
1-800-4-CANCER
LiveHelp Online Chat
NCI Home
Contact Us
Policies
Accessibility
Viewing Files
FOIA
Site Help
Site Map
Other Versions of this Site:
Mobile
|
Español
Follow Us:
Twitter
YouTube
Facebook
RSS
NIH…Turning Discovery Into Health
®